Spots Global Cancer Trial Database for Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Official Title: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
Study ID: NCT06001788
Study Description
Brief Summary: The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCI Health Chao Family Comprehensive Cancer Center, Orange, California, United States
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
The University of Kansas, Kansas City, Kansas, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Henry Ford Cancer Institute, Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Prisma Health, Greenville, South Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Clinical Development
Affiliation: Kura Oncology
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
